These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2412046)

  • 1. Ketanserin: a new hypotensive drug?
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vanhees L
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S176-82. PubMed ID: 2412046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketanserin (S2-receptor blocking agents), hypertension and chronic alcoholism.
    De Lorenzo A; Ceccanti M; Romeo M; Pisculli M; Di Giovanni MG; Lais A; Assogna G; Valgiusti FC
    Int J Clin Pharmacol Res; 1986; 6(1):77-9. PubMed ID: 2937747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
    Persson B; Gradin K; Pettersson A; Hedner T
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S22-4. PubMed ID: 2459509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of single doses of ketanserin and placebo in chronic stable angina.
    Cameron HA; Cameron CM; Ramsay LE
    Br J Clin Pharmacol; 1986 Jul; 22(1):114-6. PubMed ID: 2874825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new antihypertensive: ketanserin].
    Salvini P
    Riv Eur Sci Med Farmacol; 1989 Feb; 11(1):77-84. PubMed ID: 2678304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketanserin: haemodynamic effects and mechanism of action.
    Schalekamp MA; Woittiez AJ; Wenting GJ; van den Meiracker AH; Man in 't Veld AJ
    J Hypertens Suppl; 1986 Apr; 4(1):S7-12. PubMed ID: 2871144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with ketanserin and ritanserin in hypertensive patients.
    Hedner T; Persson B
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S44-8. PubMed ID: 2459514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blockade of 5-HT2 receptors as a mechanism of antihypertensive action of ketanserin].
    Prostran M
    Srp Arh Celok Lek; 1994; 122(3-4):99-102. PubMed ID: 17972821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional haemodynamics and antihypertensive effects during long-term ketanserin treatment.
    Persson B; Petterson A; Andersson O; Berglund G; Hedner T
    J Hypertens Suppl; 1986 Apr; 4(1):S99-101. PubMed ID: 2939223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of pharmacologic blockade of serotonin receptors (S2) on arterial pressure in rats with 2 forms of hereditary arterial hypertension].
    Popova NK; Piianzin AI; Markel' AL
    Farmakol Toksikol; 1989; 52(6):58-61. PubMed ID: 2516487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.
    Novo S; Alaimo G; Abrignani MG; Giordano U; Avellone G; Pinto A; Adamo L; Cutietta A; Indovina A; Strano A
    Int J Clin Pharmacol Res; 1986; 6(3):199-211. PubMed ID: 2943685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New therapeutic outlooks in the treatment of the hypertensive patient].
    Ambrosioni E; Bacchelli S; Borghi C
    Ann Ital Med Int; 1995 Oct; 10 Suppl():78S-81S. PubMed ID: 8562273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
    Hilleman DE; Reyes AP; Wurdeman RL; Faulkner M
    J Hum Hypertens; 2001 Aug; 15(8):559-65. PubMed ID: 11494095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker.
    Rosenthal J; Koehle W; Gruebel B; Fisher R
    J Hypertens Suppl; 1986 Apr; 4(1):S85-7. PubMed ID: 2871145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of ketanserin in essential hypertension: ketanserin versus or in combination with metoprolol.
    Mauersberger H
    J Hypertens Suppl; 1986 Apr; 4(1):S73-5. PubMed ID: 2939217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.